Drug Trial Radar · NCT00045032
Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer
Last checked: Nov 20, 2026Latest source record: Apr 27, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5,099
Actual
Start
Nov 2001
Primary completion
Mar 2005
Study completion Jun 2015
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- Breast International Group; European Organisation for Research and Treatment of Cancer - EORTC; NCIC Clinical Trials Group; ETOP IBCSG Partners Foundation
- First posted
- Jan 27, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to evaluate Herceptin treatment for 1 year and 2 years (versus observation/no Herceptin) in women with HER2-overexpressing primary breast cancer who have completed (neo-)adjuvant systemic chemotherapy, definitive surgery, and radiotherapy, if applicable. Efficacy and safety will be assessed for 10 years from randomization for each participant. All participants will continue to be followed for survival until 10 years after enrollment of the last participant.
Conditions
- Breast Cancer
Interventions
HerceptinDrug
Herceptin will be given as a loading dose of 8 milligrams per kilogram (mg/kg) via intravenous (IV) infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks.
HerceptinDrug
Herceptin will be given as a loading dose of 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Disease-Free Survival (DFS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-UpTime frame: From Baseline until time of event (median of 1 year)
- Percentage of Participants With DFS Events in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-UpTime frame: From Baseline until time of event (median of 1 year)
- DFS Rate According to Kaplan-Meier Analysis in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-UpTime frame: Year 2
- DFS Rate According to Kaplan-Meier Analysis in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-UpTime frame: Year 2
- Percentage of Participants With DFS Events Compared to Observation: 8-Year Median Follow-UpTime frame: From Baseline until time of event (median of 8 years)
- DFS Rate at Year 3 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-UpTime frame: Year 3
- DFS Rate at Year 5 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-UpTime frame: Year 5
- DFS Rate at Year 7 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-UpTime frame: Year 7
- DFS Rate at Year 8 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-UpTime frame: Year 8
- Percentage of Participants With DFS Events Compared to Observation: 10-Year Maximum Follow-UpTime frame: From Baseline until time of event (maximum of 10 years)
- DFS Rate at Year 3 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-UpTime frame: Year 3
- DFS Rate at Year 5 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-UpTime frame: Year 5
- DFS Rate at Year 7 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-UpTime frame: Year 7
- DFS Rate at Year 8 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-UpTime frame: Year 8
- DFS Rate at Year 9 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-UpTime frame: Year 9
- DFS Rate at Year 10 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-UpTime frame: Year 10
Locations
203 sites in 33 countries. Site status is shown where the registry gives one.
Hospital Aleman de Buenos Aires
Buenos Aires, Buenos Aires, Argentina
Saint John of God Hospital
Geelong, Australian Capital Territory, Australia
Toowoomba Hospital
Toowoomba, Queensland, Australia
Andrew Love Cancer Centre
Geelong, Victoria, Australia
Mount Hospital
Perth, Western Australia, Australia
Landeskrankenhaus Feldkirch
Feldkirch-Tisis, Austria
Innsbruck Universitaetsklinik
Innsbruck, Austria
Landeskrankenhaus Klagenfurt
Klagenfurt, Austria
St. Vincent's Hospital
Linz Donau, Austria
Landeskrankenanstalten - Salzburg
Salzburg, Austria
Landeskrankenhaus St. Poelten
Sankt Pölten, Austria
Universitaetsklinik fuer Innere Medizin I
Vienna, Austria
Wilhelminenspital der Stadt Wien
Vienna, Austria
LKH Villach
Villach, Austria
LKH Voecklabruck
Vöcklabruck, Austria
A. oe. Krankenhaus Wiener Neustadt
Wiener Neustadt, Austria
Ziekenhuis Netwerk Antwerpen Middelheim
Antwerp, Belgium
Reseau Hospitalier De Medecine Sociale
Baudour, Belgium
Hopital Universitaire Erasme
Brussels, Belgium
Academisch Ziekenhuis der Vrije Universiteit Brussel
Brussels, Belgium
Institut Jules Bordet
Brussels, Belgium
Centre Hospitalier Notre Dame - Reine Fabiola
Charleroi, Belgium
Cazk Groeninghe - Campus St-Niklaas
Kortrijk, Belgium
Centre Hospitalier Universitaire de Tivoli
La Louvière, Belgium
U.Z. Gasthuisberg
Leuven, Belgium
Clinique Saint-Joseph
Liège, Belgium
CHU Liege - Domaine Universitaire du Sart Tilman
Liège, Belgium
Clinique Sainte Elisabeth
Namur, Belgium
Hospital Serruys Ziekenhuis
Ostend, Belgium
Centre Hospitalier Peltzer-La Tourelle
Verviers, Belgium
Hospital Sao Lucas da PUCRS
Porto Alegre, Brazil
Hospital Santa Rita
Porto Alegre, Brazil
Instituto Nacional de Cancer
Rio de Janeiro, Brazil
Faculdade De Medicina Do ABC
Santo André, Brazil
Porto Alegre Hospital
Porto Alegre, Rio Grande do Sul, Brazil
Tom Baker Cancer Centre - Calgary
Calgary, Alberta, Canada
British Columbia Cancer Agency - Centre for the Southern Interior
Kelowna, British Columbia, Canada
Fraser Valley Cancer Centre at British Columbia Cancer Agency
Surrey, British Columbia, Canada
British Columbia Cancer Agency - Vancouver Cancer Centre
Vancouver, British Columbia, Canada
British Columbia Cancer Agency - Vancouver Island Cancer Centre
Victoria, British Columbia, Canada
Showing 40 of 203 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.